卵泡抑素
内科学
内分泌学
脂肪肝
脂肪性肝炎
医学
发病机制
纤维化
疾病
作者
Arne Yndestad,John Willy Haukeland,Tuva B. Dahl,Kristian Bjøro,Ivar P. Gladhaug,Christ Berge,Jan Kristian Damås,Terese Haaland,Else Marit Løberg,Paul Linnestad,Kåre I. Birkeland,Zbigniew Konopski,Bente Lise Halvorsen,Rolf Kristian Berge,Pål Aukrust
摘要
OBJECTIVES: Recent studies suggest that activin A, a member of the transforming growth factor (TGF) superfamily, is involved in the pathogenesis of liver disorders. We sought to explore its possible role in non-alcoholic fatty liver disease (NAFLD). METHODS: Serum levels of activin A and its natural inhibitor, follistatin, were measured in patients with NAFLD (n=70) and in control subjects (n=30). Gene expression was quantified in liver biopsies obtained from patients with NAFLD (n=13) and controls (n=6). Effects of activin A were examined in Huh7 (human hepatoma cell line) hepatocytes. RESULTS: Patients with NAFLD had significantly elevated serum levels of activin A and follistatin compared with healthy controls. In patients with non-alcoholic steatohepatitis (NASH, n=38), there were particularly high levels of activin A that were significantly related to the degree of hepatic fibrosis. Liver biopsies from NAFLD patients showed a markedly increased activin A-follistatin mRNA ratio, indicating increased hepatic activin A activity. In hepatocytes, activin A enhanced the expression of collagen and TGF-beta(1), promoted matrix metalloproteinase activity, induced mitochondrial beta-oxidation, downregulated fatty acid (FA) synthase activity, promoted decreased weight percentage of saturated FAs, and altered the composition of polyunsaturated FAs. CONCLUSIONS: Our findings support the complex role of activin A in the pathogenesis of NAFLD, involving effects on fibrosis and lipid accumulation.
科研通智能强力驱动
Strongly Powered by AbleSci AI